2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: What should we remember in everyday practice?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 7-8, 2008, Pages 396-397

  Gonzaga, Carolina C ^a,b   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; MEDICAL SOCIETY; PROGNOSIS; RENOVASCULAR DISEASE; REVASCULARIZATION; RISK FACTOR;

EID: 49249099366     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.428     Document Type: Editorial

References (7)

1. Calhoun DA, Jones D, Textor S, et al. AHA Scientific Statement. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension. 2008; 51: 1403-1419.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290: 199-206.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
4. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002; 40: 892-896.
5. Textor, SC. Atherosclerotic renal artery stenosis. Overtreated but underrated? J Am Soc Nephrol. 2008; 19: 656-659.
6. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlortalidone on ambulatory and office blood pressure. Hypertension. 2006; 47: 352-358.
7. Nishizaka, MK, Zamman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16: 925-930.